The presentations were titled as, “Long-Term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia” & “Long-Term Metabolic Outcomes Associated With KarXT (Xanomeline and Trospium): Interim Results From Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5”
The P-III (EMERGENT-4 & EMERGENT-5) studies assessed KarXT’s safety, tolerability & efficacy for schizophrenia. Interim analysis, as of Aug 2023, had 718 patients receiving at least 1 dose & 134 patients completing 1yr. of treatment
The data showed overall wt. reduction in 65% of patients with 18% & 4% achieving decreases & increases in wt. (≥7% change), respectively. Patients (BMI>30kg/m^2) completing 52wks. of treatment had an avg. wt. reduction of 2.6kg with a mean wt. reduction of 4.1kg
Ref: BMS | Image: BMS
Related News:- BMS’ Reblozyl Gains CHMP’s Positive Opinion to Treat Transfusion-Dependent Anemia Due to Myelodysplastic Syndrome (MDS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
